Lind group discloses 9.35% Bionano Genomics (BNGO) stake capped at 9.9%

Rhea-AI Filing Summary

Bionano Genomics, Inc. received an updated ownership report from Lind Global Fund III and related parties. The reporting group, which includes Lind Global Fund III LP, Lind Global Partners III LLC, and Jeff Easton, reports beneficial ownership of 1,050,000 shares of common stock, representing 9.35% of the outstanding class as of December 31, 2025.

The position consists of 525,000 Series E warrants and 525,000 Series F warrants to purchase common stock. These warrants are subject to a 9.9% beneficial ownership cap, meaning they cannot be exercised if such exercise would push the holders’ ownership above that threshold. The reporting persons certify that the securities were not acquired to change or influence control of Bionano Genomics.

Insights

Equity ownership and disclosure analyst

Updated 13G/A shows a 9.35% passive stake with warrant caps.

The filing discloses that Lind Global Fund III LP, its general partner Lind Global Partners III LLC, and individual Jeff Easton together beneficially own 1,050,000 Bionano Genomics common shares, or 9.35% of the class, as of December 31, 2025.

The stake is entirely through 525,000 Series E Warrants and 525,000 Series F Warrants. Both series include a 9.9% beneficial ownership limitation, so exercises are structurally constrained from crossing that level, which can limit immediate dilution and keep the position just below key reporting thresholds.

The reporting group files on a Schedule 13G/A and explicitly certifies that the securities are not held for the purpose of changing or influencing control. Future company filings may clarify any changes in this ownership percentage if additional exercises or transactions occur.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Bionano Genomics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

09075F404

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 09075F404

1

Names of Reporting Persons

Lind Global Fund III LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,050,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,050,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,050,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.35 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The reporting person's ownership consists of (i) 525,000 warrants to purchase shares of common stock (the "Series E Warrants") and (ii) 525,000 shares of common stock (the "Series F Warrants"). Such warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%.

SCHEDULE 13G

CUSIP No. 09075F404

1

Names of Reporting Persons

Lind Global Partners III LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,050,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,050,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,050,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.35 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The reporting person's ownership consists of (i) 525,000 Series E Warrants and (ii) 525,000 Series F Warrants. Such warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%.

SCHEDULE 13G

CUSIP No. 09075F404

1

Names of Reporting Persons

EASTON JEFF

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,050,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,050,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,050,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.35 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The reporting person's ownership consists of (i) 525,000 Series E Warrants and (ii) 525,000 Series F Warrants. Such warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Bionano Genomics, Inc.
(b)	Address of issuer's principal executive offices: 9540 Towne Centre Drive, Suite 100, San Diego, California, 92121
Item 2.
(a)	Name of person filing: This statement is filed by the following entities and individuals (collectively, referred to as the "Reporting Persons"): o Lind Global Fund III LP, a Delaware limited partnership; o Lind Global Partners III LLC, a Delaware limited liability company; and o Jeff Easton, an individual and a citizen of the United States of America. Lind Global Partners III LLC, the general partner of Lind Global Fund III LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP. Jeff Easton, the managing member of Lind Global Partners III LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP.
(b)	Address or principal business office or, if none, residence: The address of the principal business office for each of the Reporting Persons is: 444 Madison Ave, Floor 41 New York, NY 10022
(c)	Citizenship: See Row 4 of cover page for each Reporting Person.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 09075F404
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Row 9 of cover page for each Reporting Person.
(b)	Percent of class: See Row 11 of cover page for each Reporting Person.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lind Global Fund III LP

Signature:	By: Lind Global Partners III LLC, its General Partner, By: /s/ Jeff Easton
Name/Title:	Jeff Easton, Managing Member
Date:	02/17/2026

Lind Global Partners III LLC

Signature:	/s/ Jeff Easton
Name/Title:	Jeff Easton, Managing Member
Date:	02/17/2026

EASTON JEFF

Signature:	/s/ Jeff Easton
Name/Title:	Jeff Easton
Date:	02/17/2026

FAQ

What ownership stake in Bionano Genomics (BNGO) is reported in this Schedule 13G/A?

The filing reports that the Lind-related reporting persons beneficially own 1,050,000 shares of Bionano Genomics common stock, representing 9.35% of the outstanding class as of December 31, 2025. This entire position is held through Series E and Series F warrants.

Who are the reporting persons in the Bionano Genomics (BNGO) Schedule 13G/A?

The reporting persons are Lind Global Fund III LP, Lind Global Partners III LLC, and Jeff Easton. Lind Global Partners III LLC is the general partner of Lind Global Fund III LP, and Jeff Easton is the managing member of Lind Global Partners III LLC, with deemed voting and dispositive power.

What securities does Lind Global hold in Bionano Genomics (BNGO) according to this filing?

The filing states that Lind Global’s beneficial ownership consists of 525,000 Series E Warrants and 525,000 Series F Warrants to purchase Bionano Genomics common stock. Together, these instruments correspond to 1,050,000 shares beneficially owned for reporting purposes under Schedule 13G/A.

Is there a beneficial ownership limit on Lind Global’s Bionano Genomics (BNGO) warrants?

Yes. Both the Series E Warrants and Series F Warrants include a 9.9% beneficial ownership limitation. They may not be exercised if, after exercise, the reporting person’s beneficial ownership of Bionano Genomics common stock would exceed 9.9%, effectively capping exercisable ownership at that level.

Does this Schedule 13G/A indicate an attempt to control Bionano Genomics (BNGO)?

The reporting persons expressly certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Bionano Genomics. They also state that the holdings are not part of any transaction intended to have that control-related effect.

What is the event date covered in this Bionano Genomics (BNGO) Schedule 13G/A amendment?

The date of the event that triggered this Schedule 13G/A amendment is December 31, 2025. That date is used for determining the beneficial ownership information, including the 1,050,000 shares and the 9.35% percentage of the common stock class.